Pacific Biosciences of California (PACB) 2017年年度报告「NASDAQ」.pdf

1、2017 Annual Report?In 2017,we grew our product and service revenue by 19%over 2016;however,2017 was also a challengingowe er,2o chal nginga016y 1rvcI ovand serewenueur pro0year for us.It was our second full year of selling our latest DNA sequencing platform,the SequelulNAgasrtas System,and we Sspent

2、 the first half of the year continuing to deal with issues that are typical of a new product launch,includingw eng at sinconsistent system performance.In July,we provided product updates to our customers that resolved a majority of our cfrisod a ms thastoce.prodmsyweatesem pJovidect nsistthose issue

3、s,which led to a significant improvement in system utilization in the second half of the year.Our total aaiconsumables sales grew by 75%year-over-year,and,importantly,our Sequel consumable sales grew more than 8-fold cblqoreudlyearyouewyear-over-year.For the fourth quarter of 2017,the average annual

4、ized consumable revenue per installed Sequel anuelne revtallper iSeovrth qnnuyeage20For-yea,tharterzed ce finstrument(“pull-through revenue”)was over$180,000.We believe this growth in system utilization is a strong indicator 0$of both the growing interest in SMRTeofnSMowi Sequencing and our future r

5、evenue growth potential.At the end of 2017,we had totef,e ha engrowrecaour an installed base of over 370 PacBioeinsor 3PacBase instruments worldwide,and cumulative scientific publications describing our aentpucrngrns d sanenwumstrumwidtechnology were in excess of 3,200.A significant highlight for us

6、 in 2017 and early 2018 has been the expansion of our business in China,whiche expaicha,sine s in Cour sit foy 201lsig17eencant ind eahgrew to over 30%of our product and service sales in 2017,compared with approximately 10%of our product and aroservice sales in 2016.We have seen rapid growth in dema